Neuland Laboratories Limited

rs,

July 31, 2025 To BSE Limited Phiroze Jeejeebhoy Towers, 25th Floor, Dalal Street, Mumbai – 400 001 The National Stock Exchange of India Ltd Exchange Pla

28.9%

PAT* (Rs. Cr) EPS (Rs.) . 4 4 4 4 . 9 1 0 4 . 2 5 1 3 . 8 5 3 3 . 6 0 0 3 . 6 8 2 1 28.9% 20.8% 22.5% 17.3% . 3 0 9 . 7 5 6 . 2 8 5 14.4% . 1 2 4 22.1% 25.2% . 3 8 9 . 4 1

20.8%

(Rs. Cr) EPS (Rs.) . 4 4 4 4 . 9 1 0 4 . 2 5 1 3 . 8 5 3 3 . 6 0 0 3 . 6 8 2 1 28.9% 20.8% 22.5% 17.3% . 3 0 9 . 7 5 6 . 2 8 5 14.4% . 1 2 4 22.1% 25.2% . 3 8 9 . 4 1 0 1 1

22.5%

) EPS (Rs.) . 4 4 4 4 . 9 1 0 4 . 2 5 1 3 . 8 5 3 3 . 6 0 0 3 . 6 8 2 1 28.9% 20.8% 22.5% 17.3% . 3 0 9 . 7 5 6 . 2 8 5 14.4% . 1 2 4 22.1% 25.2% . 3 8 9 . 4 1 0 1 10.2% .

17.3%

(Rs.) . 4 4 4 4 . 9 1 0 4 . 2 5 1 3 . 8 5 3 3 . 6 0 0 3 . 6 8 2 1 28.9% 20.8% 22.5% 17.3% . 3 0 9 . 7 5 6 . 2 8 5 14.4% . 1 2 4 22.1% 25.2% . 3 8 9 . 4 1 0 1 10.2% . 0 2 3

14.4%

1 3 . 8 5 3 3 . 6 0 0 3 . 6 8 2 1 28.9% 20.8% 22.5% 17.3% . 3 0 9 . 7 5 6 . 2 8 5 14.4% . 1 2 4 22.1% 25.2% . 3 8 9 . 4 1 0 1 10.2% . 0 2 3 8.3% . 7 7 2 4.6% . 7 3 1 .

22.1%

. 6 0 0 3 . 6 8 2 1 28.9% 20.8% 22.5% 17.3% . 3 0 9 . 7 5 6 . 2 8 5 14.4% . 1 2 4 22.1% 25.2% . 3 8 9 . 4 1 0 1 10.2% . 0 2 3 8.3% . 7 7 2 4.6% . 7 3 1 . 6 6 7 . 0 9 7

25.2%

0 3 . 6 8 2 1 28.9% 20.8% 22.5% 17.3% . 3 0 9 . 7 5 6 . 2 8 5 14.4% . 1 2 4 22.1% 25.2% . 3 8 9 . 4 1 0 1 10.2% . 0 2 3 8.3% . 7 7 2 4.6% . 7 3 1 . 6 6 7 . 0 9 7 . 9 4

10.2%

% 22.5% 17.3% . 3 0 9 . 7 5 6 . 2 8 5 14.4% . 1 2 4 22.1% 25.2% . 3 8 9 . 4 1 0 1 10.2% . 0 2 3 8.3% . 7 7 2 4.6% . 7 3 1 . 6 6 7 . 0 9 7 . 9 4 2 . 6 1 2 . 7 0 1 Q1FY25

8.3%

. 3 0 9 . 7 5 6 . 2 8 5 14.4% . 1 2 4 22.1% 25.2% . 3 8 9 . 4 1 0 1 10.2% . 0 2 3 8.3% . 7 7 2 4.6% . 7 3 1 . 6 6 7 . 0 9 7 . 9 4 2 . 6 1 2 . 7 0 1 Q1FY25 Q2FY25 Q3FY25 Q

4.6%

6 . 2 8 5 14.4% . 1 2 4 22.1% 25.2% . 3 8 9 . 4 1 0 1 10.2% . 0 2 3 8.3% . 7 7 2 4.6% . 7 3 1 . 6 6 7 . 0 9 7 . 9 4 2 . 6 1 2 . 7 0 1 Q1FY25 Q2FY25 Q3FY25 Q4FY25 Q1FY26 Q1

Rs. 300.6 crore

FY25 Q1FY26 Q1FY25 Q2FY25 Q3FY25 Q4FY25 Q1FY26 Financial Highlights • Total Income for Q1FY26 at Rs. 300.6 crore (-32.4% YoY) • EBITDA for Q1FY26 at Rs. 42.1 crore (-67.2% YoY) • EBITDA Margin for Q1FY26 at 14

“22.4% $94 2034 Peptide API market is expected to grow at a 22.4% CAGR by 2034 due to growing prevalence of chronic disorders such as diabetes and obesity driving the demand for peptide therapeutic such as insulin and GLP-1 receptor agonist 2/3rd of peptides in clinical pipeline are being developed by synthetic routes while the rest are using the recombinant route.”

CAGR

1

CAGR

22.4% $94 2034 Peptide API market is expected to grow at a 22.4% CAGR by 2034 due to growing prevalence of chronic disorders such as diabetes and obesity driving the demand for peptide therapeutic such as insulin and GLP-1 receptor agonist 2/3rd of peptides in clinical pipeline are being developed by synthetic routes while the rest are using the recombinant route. Patent cliff of peptides, broadening the availability of these drugs as volume increases are expected to offset price declines Neuland has announced a capital expenditure of ₹254 crore to expand its peptide synthesizer reactor capacity from 0.5 KL to 6.37 KL. Market size considered based on actual values for the drugs approved by using NDA pathway Source data : Future Market Insights, Transparency Market Research GLP-1 - Glucagon like peptide-1 Sustainability Framework Focus Our Priorities Our Commitments Goal Area Our Key Goals (included in our Executives’ and Leaders’ Balanced Scorecard) • Effluent and Waste3’4 • Water3’4 •